Non - small Cell Lung Cancer
Conditions
Interventions
Group 1:Use Anlotinib Combined with S-1
Group 2:Anlotinib
Sponsors
Mianyang Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years, no gender limit. 2. Patients with stage IV non-small cell lung cancer confirmed by histopathology. 3. ECOG PS score: 0-2. 4. Progression or intolerance was evaluated after at least two different chemotherapy regimens in patients with negative driver genes, or progression or intolerance was evaluated after at least one TKI therapy in patients with positive driver genes (EGFR mutation or ALK rearrangement). 5. There were lesions measurable according to RECIST criteria. 6. Expected survival time >=12 weeks. 7. Normal function of major organs.
Exclusion criteria
Exclusion criteria: 1. Other malignancies within 5 years or now. 2. Pregnant or lactating patients. 3. Factors affecting oral medication (inability to swallow, chronic diarrhoea, esophageal fistula and intestinal obstruction, which significantly affect drug administration and absorption). 4. A history or habit of bleeding, regardless of its severity; Patients with bleeding or unhealed wounds after bleeding events, abnormal coagulation, ulcers, or fractures. 5. Patients who have participated in clinical trials of other drugs within 4 weeks. 6. Arteriovenous thrombosis, such as cerebrovascular accidents (including temporary ischemic stroke), deep vein thrombosis and pulmonary embolism, occurs within 6 months. 7. Other patients deemed unsuitable for inclusion by the physician. 8. Central squamous cell carcinoma of the lung squamous cell carcinoma, or non-small cell lung cancer with hemoptysis. 9. Patients who abuse psychotropic substances or have been diagnosed with mental disorders. 10. Patients who have previously received anrotinib or Tiggio. 11. Patients who had received extended field radiation therapy (EF-RT) within 4 weeks of grouping or limited field radiation therapy within 2 weeks of grouping and recommended lesion evaluation, or lesions for which efficacy evaluation was intended to be combined with local therapy (radiotherapy or radiofrequency ablation). 12. Tested positive for EGFR and ALK mutations and did not receive TKIs; Or who have not received immunotherapy. 13. Any serious or uncontrollable illness. 14. Participate in other clinical trials of antitumor drugs within 4 weeks. 15. Identified as a disease that seriously endangers patient safety or affects the completion of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete response rate;partial response rate;progression-free survival;disease control rate;effectiveness;safety; | — |
Countries
China
Contacts
Public ContactDu Xiaobo
Mianyang Central Hospital
Outcome results
None listed